Home > Back to Publisher > Report Information

Gastrointestinal Pharmaceuticals: Technologies and Markets

BCC Research
September 1, 2009
196 Pages - SKU: WA2493317

Abstract Table of Contents Related Reports

REPORT HIGHLIGHTS

Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.
The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.

CHAPTER ONE: INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THE STUDY; INTENDED AUDIENCE; SCOPE OF REPORT; METHODOLOGY AND INFORMATION SOURCES; ANALYST CREDENTIALS; RELATED BCC REPORTS; BCC ONLINE SERVICES; DISCLAIMER
CHAPTER TWO: EXECUTIVE SUMMARY: EXECUTIVE SUMMARY
CHAPTER THREE: INDUSTRY OVERVIEW: STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM; INGESTION AND PROPULSION OF FOOD; Mouth; Pharynx; Esophagus; DIGESTION AND ABSORPTION; Mouth; Stomach; Small Intestines; Physiology of Digestion; ELIMINATION; Large Intestine; LIVER, BILIARY TRACT AND PANCREAS; LIVER; BILIARY TRACT; Bilirubin Metabolism; PANCREAS; GASTROINTESTINAL TRACT DISORDERS; DYSPHAGIA; ESOPHAGEAL AND ABDOMINAL PAIN; VOMITING; INTESTINAL GAS; CONSTIPATION; DIARRHEA; GASTROINTESTINAL TRACT WALL DISORDERS; GASTRITIS; GASTROENTERITIS; PEPTIC ULCER DISEASE; GASTRIC ULCERS; DUODENAL ULCERS; INFLAMMATORY BOWEL DISEASE; ULCERATIVE COLITIS; CROHN’S DISEASE; ENTEROCOLITIS; DIVERTICULAR DISEASE; GASTROINTESTINAL TRACT MOTILITY DISORDERS; IRRITABLE BOWEL SYNDROME; INTESTINAL OBSTRUCTION; GASTROINTESTINAL MALABSORPTION DISORDERS; CELIAC DISEASE; TROPICAL SPRUE; CANCERS OF THE GASTROINTESTINAL TRACT; ESOPHAGEAL CANCER; GASTRIC CANCER; LIVER CANCER; PANCREATIC CANCER; SMALL INTESTINAL CANCER; COLONIC POLYPS AND COLON CANCER; U.S. DEMOGRAPHICS; PILL-SIZED VIDEO CAMERA; PILLCAM ESO; SMARTPILL; RADIO FREQUENCY IDENTIFICATION TECHNOLOGY; IPHONE APPLICATION; ENTERIC NERVOUS SYSTEM; INSURANCE COVERAGE; MONOCLONAL ANTIBODIES; WYETH IN SUIT WITH STATES; GENERIC INFLUENCE; BRANDED VS OTC PROTON PUMP INHIBITORS; MAIL ORDER TRENDS
CHAPTER FOUR: PRESCRIPTION PRODUCT SEGMENTS BY TYPE: ANTIDIARRHEALS; SYSTEMICALLY ACTING ANTIDIARRHEALS; OPIUM PRODUCTS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; ANTIEMETICS; LOCALLY ACTING ANTIEMETICS; CENTRALLY ACTING ANTIEMETICS; ANTIDOPAMINERGICS; ANTICHOLINERGICS; MISCELLANEOUS ANTIEMETICS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; GASTROINTESTINAL CANCER TREATMENTS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; H2 INHIBITORS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; LAXATIVES; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; PROTON PUMP INHIBITORS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; BOWEL ANTI-INFLAMMATORY; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; OTHER GASTROINTESTINAL PRODUCTS; ANTISPASMODICS; DIGESTANTS; GASTRIC ACIDIFIERS; PANCREATIC ENZYMES; EVACUANTS; MUCOSAL PROTECTANTS; PROSTAGLANDINS; STIMULANTS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE; TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH; TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS
CHAPTER FIVE: OTC PRODUCT SEGMENTS BY TYPE: ANTACIDS; SYSTEMIC ANTACIDS; Sodium Bicarbonate; NONSYSTEMIC ANTACIDS; Calcium Carbonate; Aluminum Products; Magnesium Products; Combination Products; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; LOCALLY ACTING ANTIDIARRHEALS; ADSORBENTS; INTESTINAL FLORA MODIFIERS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; H2 INHIBITORS; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; PROTON PUMP INHIBITORS; OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE); MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; LAXATIVES; MARKET SIZE AND GROWTH; COMPETITIVE STRUCTURE AND MARKET SHARE; TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH; TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS; RESEARCH AND DEVELOPMENT; METOSOLV ODT; NEXIUM LOW-DOSE ASPIRIN COMBINATION; REZONIC; SANVAR; TAK-390MR (KAPIDEX); ZENPEP; AB-1001; ALICAFORSEN; APF 530; CROFELEMER; HUMIRA; LINACLOTIDE; METHYLNALTREXONE (MNTX) (RELSTAR); MLN 0002 (VEDOLIZUMAB); ORBEC; PROCHYMAL; RENZAPRIDE; REMICADE; REZULAR; RIFAXIMAN (XIFAXAN); SUTENT; ALICAFORSEN ENEMA; DEXTOFISOPAM; EKB-569; GTI-2040; PUMOSETRAG; RDP-58; SORAPRAZAN; TALNETANT; BL-1030; BL-1050; TOTAL MARKET ANALYSIS
CHAPTER SIX: INDUSTRY PARTICIPANTS BY PRODUCT TYPE: COMPANY PROFILES; ASTRAZENECA; History; AXCAN PHARMA, INC.; History; CENTOCOR, INC.; History; EISAI, INC.; History; GENENTECH, INC.; History; GLAXOSMITHKLINE; History; JOHNSON & JOHNSON; History; MCNEIL CONSUMER HEALTHCARE; History; MERCK & CO., INC.; History; NOVARTIS INTERNATIONAL AG; History; PFIZER, INC.; History; PROCTER & GAMBLE CO.; History; ROCHE; History; SANOFI-AVENTIS; History; SALIX PHARMACEUTICALS, LTD.; History; SOLVAY PHARMACEUTICALS; History; TAKEDA PHARMACEUTICALS NORTH AMERICA; History; WYETH; History; APPENDIX: CONTACT INFORMATION FOR GASTROINTESTINAL MARKET PARTICIPANTS; 3M CORP.; ABBOTT LABORATORIES; ABEILLE PHARMA, INC.; ACAMBIS, PLC; ACE BIOSCIENCES A/S; AGI THERAPEUTICS, INC.; ALCHEMIA, LTD.; ALIZYME, PLC; ALLERGAN, INC.; ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.; ALTANA PHARMA AG; ALVINE PHARMACEUTICALS, INC.; AMARIN CORP.; AMGEN, INC.; ANTIGENICS, INC.; APOTHECON B.V.; AP PHARMA, INC.; ARCO PHARMACEUTICALS; ASPHELIA PHARMACEUTICALS, INC.; ARYX THERAPEUTICS, INC; ASTELLAS PHARMA, INC.; ASTRAZENECA, PLC; AXCAN PHARMA, INC.; BERTEK (MYLAN LABORATORIES INC.); BIOBALANCE, INC.; BIOGEN IDEC, INC.; BIOLINERX, LTD.; BRAINTREE LABORATORIES, INC.; BRISTOL-MYERS SQUIBB CO.; CELLDEX THERAPEUTICS, INC.; CENTOCOR ORTHO BIOTECH, INC.; CEPHALON, INC.; CERIMON PHARMA, INC.; CHEMOCENTRYX, INC.; CLAVIS PHARMA ASA; COSMO PHARMACEUTICALS SPA; CYTOKINE PHARMASCIENCES, INC.; DEBIOPHARM S.A; DOR BIOPHARMA, INC.; EISAI CO., LTD.; ELAN CORPORATION, PLC; EMD SERONO, INC.; ENZO; EURAND PHARMACEUTICALS, INC.; EVOKE PHARMA; FRESENIUS KABI AG; GENENTECH, INC.; GENZYME GENERAL; GLAXOSMITHKLINE, PLC; GLAXOSMITHKLINE CONSUMER HEALTHCARE; GLENMARK PHARMACEUTICALS, LTD.; H3 PHARMA, INC.; HELSINN HEALTHCARE; HOFFMAN-LAROCHE, LTD. (ROCHE); HYPERION THERAPEUTICS, INC.; IMMUCELL CORP.; ISIS PHARMACEUTICALS. INC.; JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON); JOHNSON & JOHNSON; LORUS THERAPEUTICS, INC.; MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS; MEDISCA, INC.; MERCK & CO., INC.; MONARCH LABS; NABI BIOPHARMACEUTICALS; NOVARTIS CORP.; NPS PHARMACEUTICALS, INC.; OTSUKA AMERICA PHARMACEUTICAL, INC.; PFIZER, INC.; THE PROCTER & GAMBLE CO.; PRODIGENE, INC.; PROGENICS PHARMACEUTICALS, INC.; RAVEN BIOTECHNOLOGIES, INC.; RELIANT PHARMACEUTICALS, INC.; ROXANE LABORATORIES, INC.; SALIX PHARMACEUTICALS, LTD; SANOFI-AVENTIS; SANTARUS, INC.; SCHERING AG; SCHWARZ PHARMA AG; SERONO S.A.; SHIRE PHARMACEUTICALS GROUP, PLC; SOLVAY S.A.; SUCAMPO PHARMACEUTICALS, INC.; SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC); TAKEDA PHARMACEUTICAL NORTH AMERICA; TARGACEPT, INC.; THERAVANCE, INC.; UCB PHARMA, INC.; UNIMED PHARMACEUTICALS, INC.; PHARMOS PHARMACEUTICALS, INC.; WATSON PHARMACEUTICALS, INC.; WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.)
LIST OF TABLES: SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 ($ MILLIONS); TABLE 1 CAUSES OF DIARRHEA; TABLE 2 COMMON CAUSES OF GASTRITIS; TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS; TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS); TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS; TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 8 MARKETED ANTIEMETIC PRODUCTS; TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS; TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%); TABLE 14 MARKETED H2 INHIBITORS PRODUCTS; TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%); TABLE 17 MARKETED LAXATIVE PRODUCTS; TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%); TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS; TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS; TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%); TABLE 26 MARKETED ANTISPASMODIC PRODUCTS; TABLE 27 MARKETED DIGESTANT PRODUCTS; TABLE 28 MARKETED EVACUANTS PRODUCTS; TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS; TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS; TABLE 31 MARKETED STIMULANT PRODUCTS; TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 ($ MILLIONS); TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009); TABLE 35 MARKETED OTC ANTACID PRODUCTS; TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS; TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS; TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS; TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 47 MARKETED OTC LAXATIVE PRODUCTS; TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 ($ MILLIONS); TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%); TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 ($ MILLIONS); TABLE 51 TOTAL MANUFACTURERS’ REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 ($ MILLIONS/%); TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT; TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS); TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%)
LIST OF FIGURES: SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014 ($ MILLIONS); FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS); FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%); FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS); FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS); FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS); FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS); FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 ($ MILLIONS); FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 ($ MILLIONS); FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 ($ MILLIONS); FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 ($ MILLIONS); FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS); FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 ($ MILLIONS); FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 ($ MILLIONS); FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009/%); FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%); FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%); FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%); FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%); FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS); FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%); FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 ($ MILLIONS); FIGURE 31 TOTAL MANUFACTURERS’ MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%); FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS); FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ MARKET SHARE BY TYPE, 2009 (%)

Gastrointestinal Pharmaceuticals: Technologies and Markets

Share this report

Other tasks

Research Assistance

Related Markets

Gastrointestinal Reports

Free Alert Me service